5.1 Vascular Access Types: AV Fistulas, AV Grafts, Tunneled CVCs, and KDOQI Guidelines

5.1 Vascular Access Types: AV Fistulas, AV Grafts, Tunneled CVCs, and KDOQI Guidelines

Core Curriculum Standard: Advanced clinical hemodialysis technicians must master the surgical anatomy, fluid biomechanics, and evidence-based clinical practice guidelines governing vascular access. The vascular access is the patient's 'lifeline'; deep comprehension of access types, anatomical pathways, maturation benchmarks, and catheter avoidance strategies is paramount to maximizing longevity, delivering prescribed dialysis adequacy, and minimizing life-threatening complications.

---

KDOQI Clinical Practice Guidelines and the ESKD Life-Plan

For decades, vascular access management was driven primarily by the Fistula First Breakthrough Initiative (FFBI), established in 2003 to increase native arteriovenous fistula (AVF) placement and decrease central venous catheter (CVC) dependence. While native AVFs remain the gold-standard vascular access due to lower infection rates, lower intervention rates, and superior long-term survival, rigid application of 'fistula at all costs' created unintended clinical consequences, including high primary non-maturation rates, prolonged catheter exposure during repeated salvage surgeries, and inappropriate access placement in elderly or vasculopathic patients with limited life expectancies.

The updated Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Vascular Access introduced a comprehensive paradigm shift: the ESKD Life-Plan.

The ESKD Life-Plan Framework

The ESKD Life-Plan is a patient-centered, individualized roadmap that spans the entire continuum of end-stage kidney disease. It requires the interdisciplinary team (nephrologist, vascular surgeon, clinical technician, nephrology nurse, and patient) to formulate an evolving access strategy that considers:

1. Patient Life Expectancy and Comorbidities: Severe cardiovascular disease, peripheral vascular disease, diabetes mellitus, and limited functional status dictate whether a patient can physiologically tolerate the high cardiac output demand of an AVF.
2. Vascular Anatomy and Vessel Preservation: Rigorous pre-ESRD vein mapping using duplex Doppler ultrasonography identifies target arteries and veins while safeguarding cephalic and basilic veins from venipuncture, IV lines, and peripherally inserted central catheters (PICCs).
3. Quality of Life and Personal Goals: Patient lifestyle, occupational demands, body habitus, self-cannulation aspirations (e.g., home hemodialysis), and preferences for kidney transplantation.
4. Contingency Planning: Every patient must have a primary access, a secondary backup plan, and a tertiary failure plan documented before vascular exhaustion occurs.

Catheter Reduction Benchmarks

Despite the individualized nature of the ESKD Life-Plan, KDOQI and the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease Quality Incentive Program (ESRD QIP) maintain aggressive catheter reduction goals:

• Long-term CVC Target: Maintaining a prevalent catheter rate of <10% across chronic hemodialysis facilities.
• Avoiding Catheter as Destination Therapy: Tunneled CVCs should serve strictly as bridging conduits while an AVF or AVG matures, or as a last-resort access in patients who have completely exhausted peripheral vascular sites or cannot tolerate surgical anastomosis.

---

Arteriovenous Fistulas (AVF): Surgical Anatomy and Hemodynamics

An arteriovenous fistula (AVF) is created surgically by anastomosing an autogenous native artery directly to an adjacent superficial native vein. Exposing the low-pressure, thin-walled venous system to arterial pressure and high-velocity pulsatile shear stress triggers arterialization of the vein: the vessel undergoes smooth muscle hypertrophy, luminal dilatation, and wall thickening, transforming it into a durable conduit capable of repeated large-gauge cannulation.

Surgical Creation of Native AV Fistula:

High-Pressure Arterial Inflow ===[Anastomosis]===> Arterialized Venous Outflow
  (e.g., Radial / Brachial)                          - Vessel dilates (≥6 mm)
                                                     - Walls thicken (hypertrophy)
                                                     - High flow (≥600 mL/min)

Standard Anatomical Configurations

1. Radiocephalic AVF (Brescia-Cimino Fistula):

   • Anatomy: Side-to-end or end-to-end surgical connection of the radial artery to the cephalic vein at the wrist.
   • Clinical Features: The most distal surgical option in the upper extremity, preserving all proximal venous and arterial anatomy for future access creation. It delivers lower flow rates (500 to 800 mL/min), resulting in a negligible incidence of high-output heart failure and vascular steal syndrome.
   • Limitations: High rate of early primary non-maturation (20% to 40%), especially in elderly, female, and diabetic patients with small radial arteries (<2.0 mm internal caliber) or atherosclerotic calcification.

2. Brachiocephalic AVF (Upper Arm Fistula):

   • Anatomy: Anastomosis of the brachial artery to the cephalic vein at the antecubital fossa.
   • Clinical Features: High primary patency and maturation rates (>80%) due to larger vessel calibers. Produces generous blood flows (800 to 1,500+ mL/min), readily supporting high-efficiency dialyzer blood pump speeds ($Q_b$ 400–500 mL/min).
   • Limitations: Higher risk of hemodynamically significant steal syndrome and high-output cardiac failure. A frequent complication is cephalic arch stenosis, where turbulent flow at the acute angle where the cephalic vein enters the axillary vein causes severe outflow resistance.

3. Brachiobasilic Transposition AVF (BB-AVF):

   • Anatomy: Anastomosis of the brachial artery to the basilic vein in the medial upper arm. Because the basilic vein runs deep beneath the fascia adjacent to the median nerve and brachial artery, it cannot be cannulated in its anatomical position. The vein must be surgically dissected, mobilized, tunneled anteriorly into the subcutaneous tissue, and elevated toward the skin surface (transposition/elevation).
   • Clinical Features: Excellent vessel quality and thick walls, rarely damaged by prior IV sticks. Long-term patency is outstanding once matured.
   • Limitations: Requires extensive surgical dissection, often staged in two separate procedures; causes significant post-operative arm edema, extensive surgical scarring, and prolonged time to first cannulation (often 8 to 16 weeks).

The Maturation Benchmark: The 'Rule of 6s'

Before a newly created native fistula is subjected to clinical cannulation, it must meet objective clinical and ultrasonographic maturity criteria known as the Rule of 6s:

[!WARNING] Premature Cannulation Hazard: Attempting to cannulate an immature AVF before fulfilling the Rule of 6s causes vessel wall shearing, extensive hematoma formation, pseudoaneurysm development, and permanent access destruction. Technicians must never cannulate a new fistula without an explicit written order and verification of maturity by the nephrologist or vascular surgeon.

---

Arteriovenous Grafts (AVG): Biomaterials and Configurations

When a patient's native superficial and deep venous anatomy is unsuitable for fistula creation due to sclerosis, vein destruction from past infusions, or small vessel diameters (<2.0 mm), an arteriovenous graft (AVG) is placed. An AVG involves surgical interposition of a synthetic, prosthetic biomaterial tube connecting an artery to a deep outflow vein.

Conduit Biomaterials

• Expanded Polytetrafluoroethylene (ePTFE): The historical standard synthetic material (Gore-Tex). It features a micro-porous fluoropolymer structure that provides high tensile strength, resists kinking, and allows fibrous tissue ingrowth into the outer wall.
• Early-Cannulation Grafts: Multi-layer polyurethane or composite silicone/ePTFE grafts designed with self-sealing inner elastomeric layers. These modern conduits can be cannulated within 24 to 72 hours post-surgery, serving as an alternative to temporary CVC placement in acute situations.

Common Graft Anatomical Configurations

1. Forearm Loop Graft: Anastomoses the brachial artery to the basilic or median antecubital vein at the elbow, looping down into the volar forearm. Easy to cannulate due to long superficial run, but prone to kinking at the apex of the loop.
2. Upper Arm Straight or Curved Graft: Connects the brachial artery to the axillary or basilic vein. Provides reliable high flow rates.
3. Thigh Graft (Femoral/Saphenous Loop): Anastomosed to the common femoral artery and femoral vein. Reserved strictly as a lower-extremity salvage access when all thoracic and arm vasculature is exhausted. Carries an exceptionally high risk of prosthetic infection and deep venous thrombosis.

Clinical Comparison: AVF vs. AVG

---

Central Venous Catheters (CVC): Types, Anatomy, and Risks

A central venous catheter (CVC) is a dual-lumen percutaneous conduit inserted directly into the central venous circulation, terminating at the cavoatrial junction. CVCs provide immediate blood access for hemodialysis when permanent accesses are unavailable or non-functional.

Tunneled Cuffed vs. Non-Tunneled Temporary Catheters

Tunneled Cuffed CVC Architecture:

External Hubs ===[Subcutaneous Tunnel]===(Dacron Cuff)====[Venotomy: IJV]===> SVC/Right Atrium
                                         * Tissue Ingrowth
                                         * Bacterial Barrier

1. Non-Tunneled Temporary Catheters:
   • Inserted directly through the skin into the vein without a subcutaneous tunnel (e.g., direct femoral or direct internal jugular puncture).
   • Lack a protective cuff. Restricted to inpatient intensive care emergency use for <7 to 14 days (femoral catheters strictly <48 hours) due to rapid, catastrophic bacterial colonization along the percutaneous tract.
2. Tunneled Cuffed Catheters (Permcath):
   • The catheter enters the subcutaneous tissue of the anterior chest wall, travels through a subcutaneous tunnel of 8 to 12 cm, and then enters the internal jugular vein.
   • The Dacron (Polyester) Cuff: Positioned approximately 1 to 2 cm inside the subcutaneous exit site. Within 2 to 4 weeks, local fibroblasts invade the porous Dacron fibers, creating dense tissue ingrowth. This serves two critical physiological functions:
     1. Mechanical Anchor: Firmly secures the catheter in place, preventing accidental dislodgement or migration.
     2. Biological Barrier: Obliterates the dead space of the tract, forming a biological seal that blocks the migration of cutaneous microorganisms (e.g., Staphylococcus aureus) from the exit site along the outside of the catheter into the bloodstream.

Anatomical Insertion Hierarchy: Why Subclavian Cannulation is Banned

---

Pathophysiology of Major CVC Morbidities

1. Catheter-Related Bloodstream Infection (CRBSI)

CVCs represent the single greatest infectious threat to hemodialysis patients, conferring a 2- to 3-fold higher mortality risk compared to patients dialyzing via AVF. Pathogens enter the bloodstream through two distinct pathways:

• Extraluminal Route: Microorganisms from the patient's skin flora migrate down the external surface of the catheter prior to Dacron cuff tissue incorporation.
• Intraluminal Route: Contamination of the catheter hubs during line connections and disconnections. Colonizing bacteria adhere to synthetic silicone/polyurethane surfaces, synthesizing an extracellular polysaccharide matrix known as a biofilm. Within the protective biofilm, bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus, gram-negative rods) are virtually immune to host immune phagocytosis and systemic antibiotic penetration. Untreated CRBSI seeds the systemic circulation, causing infective endocarditis, osteomyelitis, septic arthritis, and septic shock.

2. Fibrin Sheath (Fibrin Sleeve) Formation

Within 24 to 48 hours of catheter insertion, circulating fibrin, albumin, endothelial cells, and platelets adhere to the catheter's foreign polymer surface, forming a circumferential fibrin sheath that encases the outer surface and extends past the tip.

• Clinical Presentation (One-Way Check Valve): Technicians observe that saline or heparin can be flushed effortlessly through the lumens without resistance, but blood cannot be aspirated back into the syringe (or pre-pump arterial pressures drop below -250 mm Hg at minimal blood flows). During aspiration, the negative pressure pulls the flexible fibrin sheath over the side holes like a flap valve, occluding the lumen.
• Intervention: Instillation of fibrinolytic agents (e.g., recombinant tissue plasminogen activator [rt-PA] / alteplase) allowed to dwell for 30 to 120 minutes to digest the fibrin matrix, or fluoroscopy-guided percutaneous transfemoral snare stripping.

3. Central Venous Stenosis (CVS)

Mechanical abrasion of the catheter against the central vein endothelium, combined with catheter-induced turbulent flow, triggers an inflammatory cascade. Endothelial denudation leads to vascular smooth muscle migration and neointimal hyperplasia, resulting in fixed luminal narrowing of the superior vena cava, innominate, or subclavian veins.

---

Clinical Scenario: Managing Vascular Maturation Delays

A 62-year-old male with long-standing type 2 diabetes and end-stage renal disease had a left radiocephalic AV fistula created 7 weeks ago. He is currently dialyzing via a right tunneled internal jugular CVC. The nephrologist places an order: "Evaluate left radiocephalic AVF for cannulation; if ready, initiate 17-gauge needle cannulation."

The advanced technician performs a comprehensive physical assessment. Upon palpation, the thrill is localized strictly within 2 cm of the wrist anastomosis and dissipates rapidly. Auscultation reveals a high-pitched systolic bruit that vanishes during diastole. The technician uses a sterile metric caliper to measure the vessel: the vein measures 3.5 mm in diameter, is palpable only when the tourniquet is inflated, and ultrasound depth mapping reveals the vessel lies 8 mm below the epidermal surface. Color Doppler assessment reveals an access blood flow ($Q_a$) of 310 mL/min.

Clinical Synthesis and Technician Action: The technician recognizes that although the access is 7 weeks old (>6 weeks), it fails every other component of the Rule of 6s:

• Blood flow is 310 mL/min (fails the ≥600 mL/min threshold)
• Vessel diameter is 3.5 mm / 0.35 cm (fails the ≥0.6 cm threshold)
• Vessel depth is 8 mm / 0.8 cm (fails the ≤0.6 cm threshold)

The technician does not cannulate the fistula. The technician documents the objective measurements, refrains from needle insertion, and immediately reports the findings to the Registered Nurse and nephrologist. The interdisciplinary team refers the patient for a diagnostic duplex ultrasound and vascular surgery evaluation for either secondary balloon maturation (angioplasty) or superficialization.

---

Advanced Exam Traps: Vascular Access Types

• Trap 1: The Subclavian Catheter Trap. An exam scenario describes an acute hemodialysis patient with bilateral antecubital scarring where the emergency provider suggests placing a subclavian dialysis catheter because 'it is easier to dress.' This is an absolute clinical error. Subclavian cannulation causes severe subclavian stenosis in up to 50% of cases, permanently destroying the ipsilateral arm for future fistula or graft creation. The right internal jugular vein is always the preferred choice.
• Trap 2: The 'Old Fistula is Automatically Mature' Trap. An exam question may state that an AVF was created 10 weeks ago and ask if the technician can proceed with cannulation. Elapsed calendar time alone does not equal maturity. Without verified flow (≥600 mL/min), caliber (≥6 mm), and depth (≤6 mm), cannulating a non-arterialized vein will cause immediate extravasation and ruin the access.
• Trap 3: Confusing AVG and AVF Maturation Mechanics. Grafts do not 'arterialize' or grow in diameter; they are synthetic tubes with fixed calibers. The 2- to 4-week waiting period for an AVG is strictly to allow perigraft tissue incorporation (fibroblast adhesion around the external wall). Cannulating an AVG prematurely before tissue incorporation allows blood to track alongside the outside of the graft, causing a massive, uncontained perigraft hematoma and severe infection.